API Raw Material Ganciclovir Purity Ganciclovir Powder Raw Material Ganciclovir

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Ganciclovir
• Product Name: Ganciclovir
• Name: Ganciclovir Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC, UV
• Shelf Life: 2 Years
• CAS No: 82410-32-0
• Mf: C9h13n5o4
• MW: 255.23062
• Density: 1.81
• Boiling Point: Boiling Point
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

API Raw Material Ganciclovir Purity Ganciclovir Powder Raw Material Ganciclovir

Product Description

Product Details

Product name	Ganciclovir
Cas number	82410-32-0
Appearance	White powder
MF	C9H13N5O4
MW	255.23062

Ganciclovir is commonly associated with a range of serious haematological adverse effects. Common adverse drug reactions (≥1% of patients) include: granulocytopenia, neutropenia, anaemia, thrombocytopenia, fever, nausea, vomiting, dyspepsia, diarrhea, abdominal pain, flatulence, anorexia, raised liver enzymes, headache, confusion, hallucination, seizures, pain and phlebitis at injection site (due to high pH), sweating, rash, itch, increased serum creatinine and blood urea concentrations.

Application&Function

1. Induction and maintenance treatment of CMV retinitis in immunocompromised patients (including AIDS patients).
2. Prevention of cytomegalovirus infection in patients receiving organ transplants and prophylaxis of cytomegalovirus disease in HIV-positive patients with cytomegalovirus seroprevalence.
For immunodeficient patients with life-threatening or vision-related cytomegalovirus (CMV) infections, such as AIDS, exogenous immunosuppressive patients associated with organ transplantation and tumor chemotherapy.
Antiviral drugs, for the treatment of cytomegalovirus (CMV) infections caused by low immune capability.
For antiviral drugs intermediates.

Specification